United States & Eli Lilly and Company
22 shared events · Importance 7 · Last updated Apr 13, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Domestic
United States: The United States is involved in a fragile truce with Iran and its economy is showing slower-than-expected growth and elevated consumer prices, leading to potential interest rate hikes by the United States — Federal Reserve.
Eli Lilly and Company: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.
Apr 01, 2026 · 14 articles
Domestic
United States: The United States economy faces uncertainty due to new tariffs, with potential for higher inflation, dampened hiring, and increased costs for consumers and businesses.
Eli Lilly and Company: Eli Lilly and Company, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Regulatory
Eli Lilly and Company: Eli Lilly and Company is mentioned as another drugmaker that has recently announced sizeable investments in the United States.
Apr 22, 2025 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company is poised to bring a daily weight-loss pill to the UK, contributing to the competitive landscape that has challenged WW International.
May 07, 2025 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company is a major competitor to Novo Nordisk in the weight-loss and diabetes drug market, with its drug Zepbound gaining market share against Novo Nordisk's Wegovy.
Sep 10, 2025 · 6 articles
Regulatory
Eli Lilly and Company: Eli Lilly and Company agreed to lower prices for its obesity drug Zepbound and will sell a starter dose for $299 a month, with additional doses up to $449, representing $50 reductions from current direct-to-patient prices. Its sales of Zepbound have tripled this year to over $9 billion.
Nov 06, 2025 · 6 articles
Domestic
Eli Lilly and Company: Eli Lilly and Company saw gains that helped offset drops in other sectors, contributing to the overall positive market performance.
Dec 11, 2025 · 7 articles
Tech
Eli Lilly and Company: Eli Lilly and Company produces Tirzepatide and Tirzepatide, which are GLP-1 agonist drugs. The study's findings on rapid weight regain after stopping medication could affect the perceived long-term efficacy and market demand for their products.
Jan 08, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
Tech
Eli Lilly and Company: Eli Lilly and Company produces donanemab (Kisunla), one of the anti-amyloid drugs whose effectiveness was questioned by the Cochrane review, potentially impacting its sales and stock price.
Apr 16, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how United States and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.
Open Dashboard